On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy

Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the FDA-approved subcutaneous isatuximab delivery. Although a traditional subcutaneous push administered by a nurse represents a significant advancement over intravenous therapy, the on-body injector introduces unique technological features that further refine multiple myeloma care.

The device utilizes a prefilled vial system, which eliminates the requirement for complex dose-mixing protocols at the clinical level. The small, external needle-free device adheres directly to the patient’s skin. Upon pushing a button, an integrated, ultra-fine 30-gauge needle automatically inserts beneath the skin to infuse the therapeutic agent over approximately 12 to 13 minutes, retracting immediately once the dose is fully delivered.

The clinical benefits of this automated system translate into a vastly improved patient experience. In clinical trials, the on-body injector has demonstrated an exceptional safety profile, with virtually no administration-related reactions observed. Furthermore, the fine needle size makes the injection process significantly less arduous. When given an option to switch between 2 methods of administration in the phase 2 IZALCO trial (NCT05704049), an overwhelming majority of patients explicitly preferred the on-body injector over a manual subcutaneous push.

Beyond patient comfort, the technology introduces meaningful administrative flexibility. Because it relies on a prefilled syringe and automated delivery, the injector does not strictly require traditional infusion-center nursing care. Instead, it can potentially be administered with less direct attention from an oncology nurse, allowing clinics to deliver the drug outside of traditional infusion rooms.

Mikhael notes that this technology may eventually pave the way for supervised home delivery or patient self-administration, although navigating the regulatory and insurance landscapes presents hurdles in the United States. In the near term, incorporating the on-body injector into the clinic could be beneficial to both patient and providers, significantly improving the quality of care.